Navigation Links
AXL1717 Clinical Data From Ongoing Phase I/II Study in Cancer Patients Will be Released in Connection With the ASCO Meeting in Chicago, June 2010
Date:5/17/2010

STOCKHOLM, May 17, 2010 /PRNewswire/ -- Axelar AB, a Karolinska Development portfolio company, today announces that a submitted abstract has been accepted to the ASCO meeting in Chicago, June 2010.

The abstract containing preliminary clinical data will be publicly released on ASCO's website, http://www.asco.org on Thursday, May 20, 2010 at 6:00 PM (EDT).

"We are pleased that the abstract containing a preliminary update of the favorable clinical data has been accepted by 2010 Annual Meeting of the American Society of Clinical Oncology", says Johan Harmenberg, CEO Axelar AB.

About Axelar

Axelar is a Swedish biotech company founded in 2003. The company is developing an insulin-like growth factor-1 (IGF-1) receptor inhibitor for cancer treatment. Axelar is part of the Karolinska Development portfolio. http://www.axelar.se

About AXL1717

Axelar's lead compound, AXL1717, provides a novel treatment for a wide range of cancers. AXL1717 is the first targeted oral small-molecule IGF-1 receptor inhibitor with no effect on the insulin receptor. AXL1717 is presently undergoing Phase I/II clinical trials and the compound combines a superior preclinical efficacy against numerous tumors with an excellent tolerability profile. Most tumor cells are dependent on the IGF-1 receptor signal pathway and the IGF-1 receptor is therefore regarded as an excellent target for cancer therapy. To date, there are no IGF-1 receptor inhibitor drugs on the market.

About Karolinska Development

Karolinska Development manages one of the largest portfolios of life science companies in Europe. Using a unique, highly cost efficient business model, the management team guides the commercialization of world class life science innovations, helping to shape the next generation Pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects 12 compounds are undergoing clinical trials. The portfolio contains a total of 21 potential first-in-class products. http://www.karolinskadevelopment.com

For further information, please contact:

Johan Harmenberg, CEO, Axelar AB

Phone: +46-(0)705-14-54-53, e-mail: johan.harmenberg@axelar.se


'/>"/>
SOURCE Karolinska Development AB
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
2. Novavax Announces Publication of a Pre-clinical Study with its Pandemic 2009 H1N1 Influenza Virus-Like Particle (VLP) Vaccine
3. Soligenix Announces Completion of Patient Enrollment in Phase 2 Acute GVHD Prevention Clinical Trial
4. Quest PharmaTech Announces Dosing Of First Patient In Its Prostate Cancer Clinical Trial
5. Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C
6. Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy
7. Anavex reports animal study results as lead Alzheimers compound approaches phase 1 clinical trials
8. Pieris Announces Positive Preclinical Data on c-Met Anticalin Drug Program
9. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
10. Thursday News Highlights from the American Association of Clinical Endocrinologists (AACE) 19th Annual Meeting and Clinical Congress
11. Mettler Toledo and PDS Pathology Data Systems Integrate Powerful Solutions for Faster and More Accurate Preclinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Yorba Linda, Ca (PRWEB) , ... March 27, ... ... and metastatic colorectal cancer (mCRC) generally produce small, heterogeneous samples with limited tumor ... progress, analytical challenges remain to be resolved, such as the need for reliable ...
(Date:3/27/2017)... 27, 2017 The new research portal ... library of reports on Valero Energy , offering extensive ... petrochemical industries. ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO) The latest ... go green. Ethanol today, even though touted as a green ...
(Date:3/27/2017)... Israel , March 27, 2017 DarioHealth ... with mobile health and big data solutions, today announced ... party insurance coverage option for U.S. consumers who want ... DarioHealth has signed strategic alliance agreements with ... verify insurance coverage benefits, and if approved, will supply ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and ... Cell (hESC) Research - Global Strategic Business Report" report to ... ... (hESC) Research in US$ Million. Annual estimates and forecasts are provided ... derived from primary and secondary research. The report ...
Breaking Biology Technology:
(Date:3/20/2017)... , March 20, 2017 At this year,s CeBIT ... -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together ... is this year,s CeBIT partner country. At the largest German biometrics company ... use: fingerprint, face and iris recognition as well as DERMALOGĀ“s multi-biometrics system.   ... ...
(Date:3/16/2017)... March 16, 2017 CeBIT 2017 - Against identity fraud with DERMALOG ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution ... Used combined in one ... ...
(Date:3/9/2017)... Australia , March 9, 2017 ... the prestigious World Lung Imaging Workshop at the University ... , was invited to deliver the latest data to ... globally recognised event brings together leaders at the forefront ... developments in lung imaging. "The quality ...
Breaking Biology News(10 mins):